Vis børsmeldingen
NOK 70,516.20 by the issuance of 117,527 new shares, each with a nominal value
of NOK 0.6, in order to issue new shares in the Company to facilitate an
exercise of 65,500 share options and settlement of 52,027 restricted stock
units (“RSUs”) pursuant to the Company’s long-term incentive program for its
employees and the Company’s program for RSUs for the board members.
- Primary insider, Damian Marron, chairman of the board of directors, has
settled 14,012 RSUs under his RSU agreement and subscribed for 14,012 new
shares in the Company following the exercise of RSUs. The subscription price
for the RSUs was NOK 0.60 per new share.
- Primary insider, Diane Mellett, member of the board of directors, has
settled 2,020 RSUs under her RSU agreement and subscribed for 2,020 new
shares in the Company following the exercise of RSUs. The subscription price
for the RSUs was NOK 0.60 per new share.
- Primary insider, Thomas Falck, member of the board of directors, has settled
10,376 RSUs under his RSU agreement and subscribed for 10,376 new shares in
the Company following the exercise of RSUs. The subscription price for the
RSUs was NOK 0.60 per new share. In order to cover tax obligations and
payment of exercise price related to the settlement of RSUs, Thomas Falck
has elected to sell 4,041 of his subscribed 10,376 shares.
No primary insiders exercised any share options.
Following the RSU settlement and subscription of new shares and the
registration of the share capital increase pertaining to the new shares with
the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), the
above-mentioned primary insiders hold the following:
- Damian Marron holds 311,863 shares and no RSUs
- Diane Mellett holds 262,258 shares and 12,670 RSUs
- Thomas Falck holds 415,535 shares (including shares held through Sølen AS)
and no RSUs
Please see the attached notifications of trade for information regarding the
settlement of RSUs and sales of new shares, for the purpose of covering tax
obligations and paying exercise price, by the primary insiders.
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.
Kilde